- Report
- March 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 150 Pages
Global
From €4414EUR$4,850USD£3,749GBP
- Report
- March 2025
- 150 Pages
Global
From €4414EUR$4,850USD£3,749GBP
- Report
- April 2025
- 135 Pages
Global
From €2730EUR$2,999USD£2,318GBP
- Report
- January 2025
- 128 Pages
Global
From €2730EUR$2,999USD£2,318GBP
- Report
- August 2024
- 135 Pages
Global
From €2730EUR$2,999USD£2,318GBP
- Report
- July 2024
- 138 Pages
Global
From €2730EUR$2,999USD£2,318GBP
- Report
- June 2024
- 180 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- December 2024
- 30 Pages
Global
From €2503EUR$2,750USD£2,126GBP
- Report
- July 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,899GBP

The Dry Powder Inhaler (DPI) market is a segment of the respiratory drugs market. It is a device used to deliver medication to the lungs in the form of a dry powder. It is a convenient and efficient way to deliver medication to the lungs, as it does not require the use of a propellant gas. DPIs are used to treat a variety of respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver vaccines and other medications.
DPIs are becoming increasingly popular due to their convenience and effectiveness. They are also cost-effective, as they require fewer components than other inhalers. Additionally, DPIs are easy to use and can be used by patients of all ages.
Several companies are involved in the DPI market, including GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of DPIs. Show Less Read more